Clinical Trial Update: A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 long-term safety study of fostamatinib in Asian patients with rheumatoid arthritis was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2014-01-09